Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Fiche publication
Date publication
janvier 2019
Journal
European radiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HOEFFEL Christine
Tous les auteurs :
Durot C, Mulé S, Soyer P, Marchal A, Grange F, Hoeffel C
Lien Pubmed
Résumé
To determine whether texture analysis features on pretreatment contrast-enhanced computed tomography (CT) images can predict overall survival (OS) and progression-free survival (PFS) in patients with metastatic malignant melanoma (MM) treated with an anti-PD-1 monoclonal antibody, pembrolizumab.
Mots clés
Biomarkers, Metastatic melanoma, Pembrolizumab, Survival, Tomography, X-ray computed
Référence
Eur Radiol. 2019 Jan 15;: